News

Filter

Current filters:

LucentisAvastin

1 to 9 of 55 results

UPDATE: New study shows Regeneron’s Eylea is superior to rivals in DME

UPDATE: New study shows Regeneron’s Eylea is superior to rivals in DME

19-02-2015

US biotech Regeneron Pharmaceuticals today announced results from a study which show Eylea (aflibercept)…

AvastinEyleaLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsResearchUSA

Age-related macular degeneration treatment market to reach $10 billion by 2023

Age-related macular degeneration treatment market to reach $10 billion by 2023

04-12-2014

The market for treatments of age-related macular degeneration across seven major countries will almost…

AvastinEuropeEyleaFovistaLucentisMarkets & MarketingOphthalmicsPharmaceuticalUSA

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

15-09-2014

Health policies which favor using ranibizumab for treating eye disease in older people over safety concerns…

AvastinbevacizumabBiotechnologyEuropeLucentisNovartisOphthalmicsPricingRanibizumab InjectionRoche

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

16-06-2014

Steven Bradshaw, a UK-based drug policy expert and former ophthalmologist, is disappointed at the news…

AvastinEuropeItalyLucentisOphthalmicsPharmaceuticalRegulationRoche

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

1 to 9 of 55 results

COMPANY SPOTLIGHT

Menarini

Back to top